| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
The aims of this proteomic analysis for lung cancer patients combined with IIPs are follows; the first is to discover biomarkers to predict the acute exacerbation （AE) of IIPs caused by chemotherapy, the second is to discover useful biomarkers for diagnosis of AE of IIPs. In clinical trials, AE of IIPs was occurred in five cases out of fifty case. The two cases were compared with two control cases who did not occur an AE during all clinical course. Proteomic analyses of serum samples were performed using antibody array. In AE cases, IL-12, -16, 22, -33, MMP-10, -11, -19, and TGF-beta1 were up-regulated at the onset of AE. ANd Angiopoietin-1, -2, c-Kit, IGF-BP3, PDGFB, TGF-beta2, TGF-beta-receptor3 were down-regulated. In comparison two AE cases with two control cases E-cadherin, FGF-acidic, GM-CSF, INF-beta, and IGF-II were relatively high. And beta2-microglobulin, Bone BMP-7, CD14, CRP, HER3, IL-6, MCP-2, MMP-10, NGF-beta, TNF-alfa, TGF-beta2 were relatively low.
|
